IBS treatment market growing at CAGR of 10% to 2026 02-Aug-2019 By Ben Hargreaves The IBS treatment market will develop to be worth $3.3bn by 2026, driven by increased uptake of small molecule treatments and growing incidence.
Mallinckrodt revises plans for generic business spin-off 28-May-2019 By Ben Hargreaves Mallinckrodt states that its specialty branded portfolio will be named Sonorant Therapeutics and, in a U-turn, this side of the business will take Amitiza with it.